---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-289409"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2026-06-30T12:02:16+00:00"
generated_at: "2026-06-30T12:05:31.102465+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke completes enrollment of 162 patients in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome

## Summary
- Completed enrollment of 162 patients in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome.
- Plans to initiate rolling NDA submission to FDA in Q1 2027; data readout anticipated in Q3 2027.
- Approximately 50 of 162 patients have passed 28-week primary endpoint measurement; no discontinuations.
- Additional cohort of ~30 patients enrolling in Europe; last patient expected in August.
- Potential FDA approval and U.S. launch by early 2028.

## SEC filing metadata
- accession: 0001193125-26-289409
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2026-06-30T12:02:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312526289409/0001193125-26-289409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312526289409/d924679d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-289409
- JSON: https://secwatch.observer/filing/0001193125-26-289409.json
- Plain text: https://secwatch.observer/filing/0001193125-26-289409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.